[go: up one dir, main page]

SG125910A1 - Prevention of migraine recurrence - Google Patents

Prevention of migraine recurrence

Info

Publication number
SG125910A1
SG125910A1 SG200300769A SG200300769A SG125910A1 SG 125910 A1 SG125910 A1 SG 125910A1 SG 200300769 A SG200300769 A SG 200300769A SG 200300769 A SG200300769 A SG 200300769A SG 125910 A1 SG125910 A1 SG 125910A1
Authority
SG
Singapore
Prior art keywords
prevention
migraine recurrence
migraine
recurrence
Prior art date
Application number
SG200300769A
Other languages
English (en)
Inventor
Neville Colin Jackson
Stephen Uden
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG125910A1 publication Critical patent/SG125910A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
SG200300769A 1998-07-30 1999-06-14 Prevention of migraine recurrence SG125910A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9816556.6A GB9816556D0 (en) 1998-07-30 1998-07-30 Therapy

Publications (1)

Publication Number Publication Date
SG125910A1 true SG125910A1 (en) 2006-10-30

Family

ID=10836395

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200300769A SG125910A1 (en) 1998-07-30 1999-06-14 Prevention of migraine recurrence

Country Status (36)

Country Link
EP (3) EP1100499B1 (sh)
JP (1) JP3824863B2 (sh)
KR (2) KR100441732B1 (sh)
CN (2) CN1155379C (sh)
AP (1) AP1402A (sh)
AT (1) ATE261304T1 (sh)
AU (1) AU3952199A (sh)
BG (1) BG65309B1 (sh)
BR (1) BR9912588A (sh)
CA (1) CA2338901C (sh)
CZ (1) CZ2001357A3 (sh)
DE (1) DE69915486T2 (sh)
DK (1) DK1100499T3 (sh)
EA (2) EA200201149A1 (sh)
EE (1) EE04703B1 (sh)
ES (1) ES2214027T3 (sh)
GB (1) GB9816556D0 (sh)
GE (2) GEP20043157B (sh)
HK (1) HK1038198A1 (sh)
HR (1) HRP20010079A2 (sh)
HU (1) HUP0103424A3 (sh)
ID (1) ID26996A (sh)
IL (1) IL140169A0 (sh)
IS (1) IS2253B (sh)
NO (1) NO20010489L (sh)
NZ (2) NZ508736A (sh)
OA (1) OA11576A (sh)
PL (1) PL194611B1 (sh)
PT (1) PT1100499E (sh)
SG (1) SG125910A1 (sh)
SK (1) SK1182001A3 (sh)
TR (1) TR200100314T2 (sh)
TW (2) TWI248362B (sh)
UA (1) UA76399C2 (sh)
WO (1) WO2000006161A1 (sh)
YU (2) YU6401A (sh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CN1176649C (zh) * 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
US7332183B2 (en) * 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
EP1615635A1 (en) 2003-04-11 2006-01-18 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
CA2765866C (en) 2008-06-20 2016-06-21 Alphapharm Pty Ltd Single phase pharmaceutical composition of a 5-ht1 inhibitor and an nsaid
EP2490669B1 (en) 2009-10-23 2017-01-11 Fortuderm Ltd. Triptans for the treatment of psoriasis
MY169068A (en) * 2012-04-18 2019-02-12 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
CN103385876B (zh) * 2012-05-08 2016-01-13 四川滇虹医药开发有限公司 一种夫罗曲坦的药物组合物及其制备方法
CN104523709A (zh) * 2014-12-22 2015-04-22 青岛正大海尔制药有限公司 一种含有琥珀酸夫罗曲坦的复方缓释制剂
US11975104B2 (en) 2016-07-11 2024-05-07 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006842A1 (en) * 1994-08-27 1996-03-07 Pfizer Limited Salts of an anti-migraine indole derivative
WO1999001135A1 (en) * 1997-07-03 1999-01-14 Pfizer Limited Pharmaceutical compositions containing eletriptan hemisulphate and caffeine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2575272B2 (ja) * 1990-10-15 1997-01-22 フアイザー・インコーポレイテツド インドール誘導体
EP0546593B1 (en) * 1991-10-30 1997-09-03 Glaxo Group Limited Multi-layered compositions containing histamine or serotonin antagonists
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5744482A (en) * 1994-10-05 1998-04-28 Eli Lilly And Company Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
IL127955A0 (en) * 1996-07-11 1999-11-30 Farmarc Nederland Bv Pharmaceutical composition containing acid addition salt of basic drug
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006842A1 (en) * 1994-08-27 1996-03-07 Pfizer Limited Salts of an anti-migraine indole derivative
WO1999001135A1 (en) * 1997-07-03 1999-01-14 Pfizer Limited Pharmaceutical compositions containing eletriptan hemisulphate and caffeine

Also Published As

Publication number Publication date
IL140169A0 (en) 2002-02-10
EP1466601A3 (en) 2005-04-13
EA200100089A1 (ru) 2001-08-27
JP2002521446A (ja) 2002-07-16
PT1100499E (pt) 2004-06-30
PL194611B1 (pl) 2007-06-29
BG65309B1 (bg) 2008-01-31
DE69915486T2 (de) 2005-03-03
HUP0103424A2 (hu) 2002-02-28
BG105277A (en) 2001-11-30
TW537893B (en) 2003-06-21
HK1038198A1 (en) 2002-03-08
EP1100499A1 (en) 2001-05-23
KR100441732B1 (ko) 2004-07-27
CN1522697A (zh) 2004-08-25
TWI248362B (en) 2006-02-01
CA2338901A1 (en) 2000-02-10
NZ508736A (en) 2003-09-26
HUP0103424A3 (en) 2003-05-28
KR20030078876A (ko) 2003-10-08
YU20303A (sh) 2006-08-17
AU3952199A (en) 2000-02-21
NO20010489L (no) 2001-03-26
JP3824863B2 (ja) 2006-09-20
EE200100061A (et) 2002-06-17
EP1435237A1 (en) 2004-07-07
TW200300674A (en) 2003-06-16
ID26996A (id) 2001-02-22
DE69915486D1 (de) 2004-04-15
AP2001002056A0 (en) 2001-03-31
ATE261304T1 (de) 2004-03-15
IS5771A (is) 2000-12-15
CN1309560A (zh) 2001-08-22
DK1100499T3 (da) 2004-06-14
PL345803A1 (en) 2002-01-02
WO2000006161A1 (en) 2000-02-10
OA11576A (en) 2004-07-01
GEP20043157B (en) 2004-01-26
ES2214027T3 (es) 2004-09-01
UA76399C2 (en) 2006-08-15
BR9912588A (pt) 2001-05-02
EA004036B1 (ru) 2003-12-25
TR200100314T2 (tr) 2001-06-21
CA2338901C (en) 2008-02-19
EP1100499B1 (en) 2004-03-10
IS2253B (is) 2007-06-15
HRP20010079A2 (en) 2002-02-28
YU6401A (sh) 2004-03-12
GEP20063719B (en) 2006-01-10
KR20010079582A (ko) 2001-08-22
NO20010489D0 (no) 2001-01-29
CN1155379C (zh) 2004-06-30
NZ527625A (en) 2005-01-28
EE04703B1 (et) 2006-10-16
EP1466601A2 (en) 2004-10-13
CZ2001357A3 (cs) 2001-10-17
SK1182001A3 (en) 2001-10-08
EA200201149A1 (ru) 2003-02-27
AP1402A (en) 2005-04-29
GB9816556D0 (en) 1998-09-30

Similar Documents

Publication Publication Date Title
AU5100599A (en) Egf-genistein for prevention of restenosis
PL343611A1 (en) Inhibitors of caspases
IL140500A0 (en) Blast effects suppression system
ZA972000B (en) Inhibition of proliferation of cells.
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
AP2001002056A0 (en) Prevention of migraine recurrence
IL138247A0 (en) Substituted bisindolymaleimides for the inhibition of cell proliferation
AU1393799A (en) Cooling of stored water
PL342733A1 (en) Biocement of improved properties
EP1218407A4 (en) USES OF KAPPA-CONOTOXIN PVIIA
GB2341792B (en) Personal shower assembly
AU2003213493B2 (en) Prevention of migraine recurrence
HU0400568D0 (en) Prevention of migraine recurrence
HU0400567D0 (en) Prevention of migraine recurrence
SI1100499T1 (en) Use of eletriptan for the prevention of migraine recurrence
GB2339588B (en) Fire protection
GB9809889D0 (en) Prevention of restenosis
GB2378704B (en) Uses of 5t4 antigen
GB9819094D0 (en) Fire protection
TW364362U (en) Improvement on structure of protection mouth-muffle
PL326575A1 (en) Agent for all-aspect protection of wood
SI1064279T1 (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
TW353479U (en) Processing structure of filthy water
TW351085U (en) Improvement of canteen
TW346937U (en) Improvement for pressure-releasing structure of hydrant